LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.02 -2.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.96

Max

3.13

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+28.21% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

37M

1.2B

Vorige openingsprijs

5.29

Vorige sluitingsprijs

3.02

Nieuwssentiment

By Acuity

50%

50%

171 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mrt 2026, 22:51 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mrt 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mrt 2026, 20:31 UTC

Winsten

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mrt 2026, 23:49 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mrt 2026, 23:31 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery -- Market Talk

18 mrt 2026, 22:49 UTC

Marktinformatie

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mrt 2026, 22:41 UTC

Marktinformatie

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mrt 2026, 22:36 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mrt 2026, 22:24 UTC

Winsten

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mrt 2026, 21:58 UTC

Winsten

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mrt 2026, 21:55 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

18 mrt 2026, 21:55 UTC

Marktinformatie
Winsten

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mrt 2026, 21:40 UTC

Marktinformatie

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mrt 2026, 21:16 UTC

Marktinformatie

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mrt 2026, 21:00 UTC

Belangrijke Nieuwsgebeurtenissen

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mrt 2026, 20:58 UTC

Winsten

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mrt 2026, 20:41 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:29 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:25 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:17 UTC

Winsten

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mrt 2026, 20:14 UTC

Marktinformatie

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mrt 2026, 20:09 UTC

Winsten

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mrt 2026, 20:07 UTC

Winsten

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mrt 2026, 20:06 UTC

Winsten

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mrt 2026, 20:03 UTC

Winsten

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

28.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  28.21%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

171 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat